Neurological complications post - COVID-19 vaccination
DOI:
https://doi.org/10.52692/1857-0011.2024.3-80.09Keywords:
headache, neurological complications, covid-19, Guillain-Barre syndrome, multiple sclerosis, migraine, sinus thrombosis, depressionAbstract
Following vaccination of the population against Covid-19 infection, a multitude of neurological complications have been reported, from the most frequently encountered to the rarest. In our article we present a narrative analysis of two databases: PubMed and Google Scholar for all types of published studies (case reports, case series, cross-sectional study with a meta-analytic literature review, systematic review, meta-analysis, retrospective study, cohort study). Headache is one of the most publicized, early onset complications, it can be migraine type - 51.1% and tension type - 27.4%, most frequently starting after the administration of the AstraZeneca vaccine, followed by the Sputnik V vaccine. The incidence of ischemic stroke was recorded from 0.29 to 1.76 million vaccinees, while hemorrhagic stroke represents364.7 per 1 million people, developing more frequently after mRNA vaccines. MOG encephalomyelitis was also recorded postvaccination, manifested by optic neuritis, with onset 10 days after the 1st dose administered, more susceptible being after the AstraZeneca vaccine. Acute disseminated encephalomyelitis (ADEM) was reported after the SinoVac and AstraZeneca vaccines, manifesting as sensory disturbances, seizures, and focal neurological deficits. GBS after COVID-19 vaccination occurs in 8.1 per 1,000,000 vaccinations, more frequently after mRNA vaccines. Optic neuritis occurs after inactivated vaccines, adenoviral vaccines, and messenger RNA vaccines, while multiple sclerosis begins after the administration of Pfizer and AstraZeneca vaccines. Transverse myelitis and Bell’s palsy are more common with the Moderna vaccine, while sinus thrombosis and TIA develop more often after the Johnson-Johnson vaccine.
References
S. Nasergivehchi, M. Togha, E. Jafari, M. Sheikhvatan, and D. Shahamati, “Headache following vaccination against COVID-19 among healthcare workers with a history of COVID-19 infection: a cross-sectional study in Iran with a meta-analytic review of the literature,” Head Face Med, vol. 19, no. 1, Dec. 2023, doi: 10.1186/s13005-023-00363-4.
A. Chatterjee and A. Chakravarty, “Neurological Complications Following COVID-19 Vaccination,” Jan. 01, 2023, Springer. doi: 10.1007/s11910-022-01247-x.
S. Jarius, N. Bieber, J. Haas, and B. Wildemann, “MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature,” J Neurol, 2022, doi: 10.1007/ s00415-022-11194-9.
M. Yu, S. Nie, Y. Qiao, and Y. Ma, “Guillain-Barre syndrome following COVID-19 vaccines: A review of literature,” 2023, Frontiers Media S.A. doi: 10.3389/fimmu.2023.1078197.
M. Kakovan, S. Ghorbani Shirkouhi, M. Zarei, and S. Andalib, “Stroke Associated with COVID-19 Vaccines,” Jun. 01, 2022, W.B. Saunders. doi: 10.1016/j.jstrokecerebrovasdis.2022.106440.
M. Jameie et al., “Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: a cross-sectional cohort study,” Front Neurol, vol. 14, 2023, doi: 10.3389/fneur.2023.1214501.
S. Eslait-Olaciregui, K. Llinás-Caballero, D. Patiño- Manjarrés, T. Urbina-Ariza, J. F. Cediel-Becerra, and C. A. Domínguez-Domínguez, “Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature,” Jan. 01, 2023, SAGE Publications Ltd. doi: 10.1177/20420986231165674.
M. Castaldo et al., “Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis,” Dec. 01, 2022, BioMed Central Ltd. doi: 10.1186/s10194-022-01400-4.
E. Caronna et al., “Headache attributed to SARS- CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review,” Jan. 01, 2023, SAGE Publications Ltd. doi: 10.1177/03331024221131337.
J. González-Menacho, M. Villas-Roca, H. Castañé, J. Joven, J. Camps, and S. Iftimie, “Can COVID-19 vaccines relieve severe tension-type headache and migraine?,” Med Hypotheses, vol. 161, Apr. 2022, doi: 10.1016/j.mehy.2022.110812.
A. Torrente et al., “New-onset headache following COVID-19: An Italian multicentre case series,” J Neurol Sci, vol. 446, Mar. 2023, doi: 10.1016/j. jns.2023.120591.
M. Elfil et al., “Cerebral venous sinus thrombosis after COVID-19 vaccination: a case report and literature review,” Oxf Med Case Reports, vol. 2023, no. 1, pp. 30–37, Jan. 2023, doi: 10.1093/omcr/omac154.
L. M. Foo, W.-H. Wan Hitam, M. Ibrahim, and K. S. Sonny Teo, “Extensive Cerebral Venous Sinus Thrombosis Post COVID-19 Vaccination,” Cureus, Jan. 2023, doi: 10.7759/cureus.33637.
S. A. Meo, N. Shaikh, F. A. Abukhalaf, and A. S. Meo, “Exploring the adverse events of Oxford– AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain– Barré Syndrome,” Sci Rep, vol. 14, no. 1, Dec. 2024, doi: 10.1038/s41598-024-66999-7.
P. Neophytou, A. Artemiadis, G. M. Hadjigeorgiou, and P. Zis, “Miller Fischer syndrome after COVID-19 infection and vaccine: a systematic review,” Oct. 01, 2023, Springer Science and Business Media Deutschland GmbH. doi: 10.1007/s13760-023-02336-5.
D. Alijanzadeh et al., “Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies,” BMC Neurol, vol. 23, no. 1, Dec. 2023, doi: 10.1186/s12883-023-03375-4.
T. L. Xiao, A. Zaharia, A. S. Al-Smadi, and C. J. Murphy, “Transverse myelitis following bivalent COVID-19 booster vaccine and quadrivalent seasonal influenza vaccine,” Aug. 01, 2023, John Wiley and Sons Inc. doi: 10.1111/cen3.12742.
I. Lotan, M. Lydston, M. Levy, B. Chwalisz, and M. J. Dinkin, “Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review,” Journal of Neuro-Ophthalmology, vol. 42, no. 2, pp. 154–162, Jun. 2022, doi: 10.1097/WNO.0000000000001537.
M. Alluqmani, “New Onset Multiple Sclerosis Post- COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study,” Cureus, Mar. 2023, doi: 10.7759/cureus.36323.
K. Toljan, M. Amin, A. Kunchok, and D. Ontaneda, “New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure,” J Neuroimmunol, vol. 362, Jan. 2022, doi: 10.1016/j.jneuroim.2021.577785.
E. C. Tallantyre et al., “COVID-19 Vaccine Response in People with Multiple Sclerosis,” Ann Neurol, vol. 91, no. 1, pp. 89–100, Jan. 2022, doi: 10.1002/ana.26251.
S. Zhao, S. Toniolo, A. Hampshire, and M. Husain, “Effects of COVID-19 on cognition and brain health,” Nov. 01, 2023, Elsevier Ltd. doi: 10.1016/j.tics.2023.08.008.
A. De Souza, R. Jacques, and S. Mohan, “Vaccine- Induced Functional Neurological Disorders in the Covid-19 Era,” May 01, 2023, Cambridge University Press. doi: 10.1017/cjn.2022.48.
B. Chaurasia, V. Chavda, B. Lu, K. Garg, and N. Montemurro, “Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination,” Brain Behav Immun Health, vol. 22, Jul. 2022, doi: 10.1016/j.bbih.2022.100463.
H. J. Kim, M. H. Kim, M. G. Choi, and E. M. Chun, “Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea,” Mol Psychiatry, 2024, doi: 10.1038/s41380-024-02627-0.
R. Hosseini and N. Askari, “A review of neurological side effects of COVID-19 vaccination,” Dec. 01, 2023, BioMed Central Ltd. doi: 10.1186/s40001-023-00992-0.
K. Shahsavarinia et al., “Bell’s Palsy and COVID-19 Vaccination: A Systematic Review,” Med J Islam Repub Iran, vol. 36, no. 1, 2022, doi: 10.47176/mjiri.36.85.
A. Vogrig et al., “Central nervous system immune- related disorders after SARS-CoV-2 vaccination: a multicenter study,” Front Immunol, vol. 15, 2024, doi: 10.3389/fimmu.2024.1344184.
I. M. Dighriri et al., “Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review,” Cureus, Mar. 2022, doi: 10.7759/ cureus.23526.
C. M. Marra, C. Jose, T. Rudroo, and L. Chamard- Witkowski, “OPEN ACCESS EDITED AND REVIEWED BY Editorial: The NeuroCOVID- syndrome: cognitive and psychological profiles, physiopathology, and impact on neurologically vulnerable populations,” 2024, doi: 10.1001/jamaneurol.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
